Component
Peripapillary retinal nerve fibre layer thickness
Peripapillary retinal nerve fibre layer thickness. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
Where it participates (unsigned role)
Out of 88 patients exposed to vigabatrin in infancy, 28 were able to perform formal visual field testing, mild vigabatrin-attributed visual field defect was found in four patients and severe defect in one, median vigabatrin treatment duration for those with normal visual field was 11 months compared to 19 months for those with the defect, optical coherence tomography showed concomitant attenuated retinal nerve fiber layer in three children, and the overall prevalence after exposure in infancy is lower than the 52% which has been reported after exposure in adulthood while the risk increases with longer treatment duration.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/gaba-research/34716587.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "30459a805ac23ba0a6f0cb4c9484da96a968609466a4bb1fc7c41636542ba887", "start_char": 0, "end_char": 1403, "text_sha256": "30459a805ac23ba0a6f0cb4c9484da96a968609466a4bb1fc7c41636542ba887"}
- experimental_model
- Retrospective population-based perimetry and optical coherence tomography at school age in children exposed in infancy
- exposure
- Vigabatrin given for infantile spasms, with visual fields and retinal nerve fibre layer measured years later
- limitations
- Only 28 of 88 exposed patients could perform formal visual field testing, which limits the prevalence estimate in both directions.
- nutrient_topic
- GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. · Gamma-aminobutyric acid
- organism
- Human
- plain_language
- The drug that raises brain GABA costs some patients their peripheral vision, and the longer they take it the likelier that is.
- primary_references
- [gb-p34716587] Visual field defects after vigabatrin treatment during infancy: retrospective population-based study. (2022). https://pubmed.ncbi.nlm.nih.gov/34716587/ DOI: 10.1111/dmcn.15099
- tissue_or_cell_type
- Retina
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Retrospective population-based perimetry and optical coherence tomography at school age in children exposed in infancy · source_derived_draft · unverified_draft
### gb-duration-drives-the-field-loss Out of 88 patients exposed to vigabatrin in infancy, 28 were able to perform formal visual field testing, mild vigabatrin-attributed visual field defect was found in four patients and severe defect in one, median vigabatrin treatment duration for those with normal visual field was 11 months compared to 19 months for those with the defect, optical coherence tomography showed concomitant attenuated retinal nerve fiber layer in three children, and the overall prevalence after exposure in infancy is lower than the 52% which has been reported after exposure in adulthood while the risk increases with longer treatment duration. Condition category: normal nutrient_topic: GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. plain_language: The drug that raises brain GABA costs some patients their peripheral vision, and the longer they take it the likelier that is. organism: Human tissue_or_cell_type: Retina experimental_model: Retrospective population-based perimetry and optical coherence tomography at school age in children exposed in infancy limitations: Only 28 of 88 exposed patients could perform formal visual field testing, which limits the prevalence estimate in both directions. exposure: Vigabatrin given for infantile spasms, with visual fields and retinal nerve fibre layer measured years later evidence_span: {"source_cache": "artifacts/gaba-research/34716587.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "30459a805ac23ba0a6f0cb4c9484da96a968609466a4bb1fc7c41636542ba887", "start_char": 0, "end_char": 1403, "text_sha256": "30459a805ac23ba0a6f0cb4c9484da96a968609466a4bb1fc7c41636542ba887"} [gb-p34716587] Visual field defects after vigabatrin treatment during infancy: retrospective population-based study. (2022). https://pubmed.ncbi.nlm.nih.gov/34716587/ DOI: 10.1111/dmcn.15099
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.